Post-Surgical Healing

Using the Assisi products immediately after a surgical procedure and in the days after surgery enhances healing by accelerating the reduction of swelling and pain. The tPEMF® system can manage post-surgical inflammation as well as wound healing, enabling rehabilitation to begin more quickly and safely. The device is simple to use. It may be placed directly over any wound dressing and non-metallic splints. A single manual treatment lasts only 15 minutes. Similar technology has been cleared by the FDA specifically for the treatment of post-operative pain and edema in humans.

Assisi products can be supplied to treat post-procedural sites with a pre-programmed treatment regimen, which improves compliance and thereby enhances outcomes.

Published studies have shown that tPEMF:

  • Accelerates surgical wound healing by up to 58%1
  • Accelerates tendon repair by up to 69%2
  • Accelerates the growth of new blood vessels that support tissue healing 3,4

1Strauch B, Patel MK, Rosen DJ, Mahadevia S, Brindzei N, Pilla AA. 2006. Pulsed magnetic field therapy increases tensile strength in a rat Achilles’ tendon repair model. Journal of Hand Surgery. 31:1131-1135
2Strauch B, Patel MK, Navarro A, Berdischevsky M, Pilla AA. 2007. Pulsed magnetic fields accelerate wound repair in a cutaneous wound model in the rat. Plast Reconstr Surg 120:425-430
3Roland D, Ferder M, Kothuru R, Faierman T, Strauch B. 2000. Effects of pulsed magnetic energy on a microsurgically transferred vessel. Plast Reconstr Surg 105:1371-1374.
4Weber RV, Navarro A, Wu JK, Yu HL, Strauch B. 2004. Pulsed magnetic fields applied to a transferred arterial loop support the rat groin composite flap. Plast Reconstr Surg 114:1185-1189


What is an NPAID?

Quite simply, NPAID refers to the class of medical devices that employ some form of electromagnetic therapy in the treatment of inflammatory conditions in humans and animals (non-pharmaceutical anti-inflammatory devices). The term has been coined to emphasize this technology as a non-pharmaceutical option to non-steroidal anti-inflammatory drugs (NSAIDs), the most commonly prescribed class of drugs for treating pain and inflammation in humans and animals.

NSAIDs, steroids, and opiates are three classes of pharmaceutical treatments that are part of the standard of care for certain inflammatory and traumatic conditions. NPAIDs that employ specifically targeted electromagnetic waveforms constitute a fourth class of treatment for treating inflammation and managing pain in humans and animals.

See the Interview on Youtube.

NPAIDs may be used to treat:

  • Orthopedic injuries
  • Degenerative disorders
  • Neurological issues
  • Post-surgical pain & swelling
  • Inflammatory conditions
  • Wounds

When the complications of standard treatments narrow, consider an NPAID.

How does an NPAID work?

The mechanism of action for any type of NPAID depends on the specific configuration and intensity of the electromagnetic waveform within the part of the spectrum that is employed by the device. 

Pulsed electromagnetic field (PEMF) technology is an increasingly recognized member of this class of devices. PEMF devices typically employ electric microcurrents to generate a low-intensity, sub-thermal, pulsed electromagnetic field.

The configuration and intensity of the resultant electromagnetic waveform can be targeted to enhance a specific biological and chemical reaction in human and animal tissues. For example, the FDA-cleared PEMF waveform long used in bone growth stimulators promotes calcium formation in recalcitrant fractures. Another patented PEMF waveform cleared by the FDA for reducing postoperative pain and edema has been targeted to enhance the production of nitric oxide in damaged tissues and to stimulate vasodilation for increased blood flow.

Assisi targeted PEMF (tPEMF)® technology summary

Assisi’s targeted pulsed electromagnetic field technologies emerge out of a century-long evolution of using electrical currents to improve health and healing. Pulsed electromagnetic fields are simply delivery systems for inducing electrical current. Pulsing an electromagnetic field near a conductor (such as tissue) will induce current flow in the conductor.

This simple law from physics allows currents to be induced in tissue from outside the body, without anything touching the skin. Magnetic fields penetrate through bandages, casts, fur, hair etc. The simple induction of electrical current in tissue is the functional therapeutic component of Assisi’s tPEMF® technology.

Historically, PEMF technologies were generally large, AC-powered devices that produced a substantial magnetic field. Even today, manufacturers of some PEMF devices describe them as “powerful” or “more powerful”. During much of this period of development, PEMF devices did not have a specific or known biological target. Developing medical applications of the technology was largely driven by trial and error based on unproven assumptions that greater power was likely to produce better outcomes.

We now know those assumptions to be incorrect. By the 1970s, researchers and clinicians had developed relatively low-powered PEMF devices – bone growth stimulators (BGS) – to heal recalcitrant fractures. Although demonstrated to be effective at fracture repair at low power, the specific mechanism of action remained elusive.

Arthur A. Pilla, one of the inventors of BGS technology and a professor of Biomedical Engineering at Columbia University, was also the original developer of Assisi’s targeted PEMF products. He focused significant time and resources on researching mechanisms of action for PEMF and developing PEMF signals. Among the potential targets proposed in the literature, research suggested that calcium binding was a likely candidate, in particular, the binding of calcium (Ca) to calmodulin (CaM). This particular complex is a voltage-dependent process responsible for a number of potentially therapeutic biological cascades, most importantly the natural anti-inflammatory cascade.

Learn more about the science behind the technology here.

The Ca/CaM anti-inflammatory cascade is well described. The initial binding of four calcium ions to calmodulin produces a conformational change in CaM, which, in turn, then binds to the constitutive nitric oxide syntheses (both endothelial – eNOS and neuronal – nNOS), which virtually immediately (within seconds) leads to the production of nitric oxide (NO), a principal anti-inflammatory molecule. Nitric oxide reduces pain, improves blood flow and reduces edema. It further triggers downstream effects, including the production of cGMP, the ‘energy’ molecule that then drives growth factor production, which, in turn, support new blood vessel formation, tissue regeneration and then, ultimately, to tissue remodeling.

What this means is that Assisi can bring the most effective targeted PEMF technology to veterinary medicine in small, lightweight and disposable configurations whose effectiveness is supported by a substantial and growing body of basic science and clinical research.